Inhalon Doses First Patient in Phase 1 Study of Inhaled IN-006 to Treat COVID-19
Inhalon Biopharma, Inc., a clinical-stage immunotherapy company developing an inhaled “muco-trapping” antibody platform for treating acute respiratory infections, today announced that the first patient has been dosed in a Phase 1 safety and tolerability study of IN-006 in healthy volunteers. IN-006 is an inhaled, muco-trapping formulation of regdanvimab. The study is being conducted in collaboration with Celltrion, Inc., which has already received Emergency Use Authorization (EUA) in several countries worldwide for its intravenous (IV) formulation of regdanvimab for the treatment of COVID-19.
Inhalon’s muco-trapping antibody platform directly traps the virus in airway mucus, preventing the local spread of infection and quickly eliminating the virus from the lungs through the body’s natural ability to clear mucus. Inhaled therapy can be readily self-administered by patients at home, extend critical drug supplies to more patients by reducing the dosage needed, and reduces the demand on healthcare staff and infusion clinic space that frequently accompanies IV drugs.
“There are very few options for treating patients diagnosed with COVID-19, and the concept of delivering an antibody directly to the lungs through inhaled technology has the potential to be of tremendous value to patients and health systems,” said Dr. Jason Lickliter, MBBS, FRACP, principal investigator and Chief Medical Officer at Nucleus Network, Inc. “Delivering treatment through the IV route involves a number of resources, like time, infusion clinic resources, and larger doses of medication. The development of IN-006 combines a more convenient delivery method with a promising antibody therapy to offer a potential treatment that can be self-administered at home as an early and immediate intervention for patients recently diagnosed with COVID-19.”
Celltrion has demonstrated in a Phase 3 study that regdanvimab significantly reduced the risk of COVID-19-related hospitalization or death by 72% for patients at high-risk of progressing to severe COVID-19 and 70% for all patients. Regdanvimab has demonstrated efficacy against the most common variants in in vitro or in vivo studies, including the Alpha, Beta, Gamma and Delta variants.
“COVID-19 infections in both vaccinated and unvaccinated people continue to rise and place an enormous burden on healthcare workers and hospitals,” said John B. Whelan, Inhalon’s president and chief executive officer. “Inhalon’s muco-trapping antibody technology is the only therapeutic modality that can actively clear infectious virus from the lungs via natural mucus clearance, thereby eliminating the source of inflammation and viral spread. Combining Inhalon’s inhaled, muco-trapping platform with Celltrion’s highly effective anti-SARS-CoV2 antibody will likely create a new treatment that patients can self-administer to free up valuable healthcare resources.”
People In This Post
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more